Brief: Kancera Gets Application Approval To Start Kandova Study

Novakand Pharma AB

16/02/2023 12:32

Feb 16 (Reuters) - Kancera AB  KANC.ST :
    * REPORTS THAT SWEDISH MEDICINES AGENCY HAS APPROVED
APPLICATION
TO START KANDOVA STUDY AND THAT DR HANJING XIE HAS BEEN
APPOINTED AS NEW MEDICAL DIRECTOR
    * REPORTS TODAY THAT SWEDISH MEDICINES AGENCY HAS APPROVED
CO'S
APPLICATION TO CONDUCT CLINICAL TRIAL OF CO'S
FRACTALKINE-BLOCKING DRUG CANDIDATE KAND567 IN PATIENTS WITH
OVARIAN CANCER, THE SO-CALLED KANDOVA STUDY
    * FURTHER ANNOUNCES THAT IT HAS APPOINTED DR. HANJING XIE AS
ITS
NEW CHIEF MEDICAL OFFICER (CMO)
    * DR. HANJING XIE WILL INITIALLY TAKE PART-TIME POSITION AT
KANCERA

Source text for Eikon:  ID:nMFN7tVXg0 
Further company coverage:  KANC.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))